13-Nov-2024 3:01 PM CST - Business Wire Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. At the end of October we announced that our partnership with Ono Pharmaceutical had ended following substantial non-dilutive financing that has fully fund
31-Oct-2024 6:00 AM CST - Business Wire Equillium Maintains Rights to Itolizumab Following Ono Partnership $EQ #GVHD--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equilliums rights to itolizumab to expire. The decision was not related to data from any clinical program and there have been no obse
13-Nov-2024 3:01 PM CST - Business Wire Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the third quarter 2024 and provided corporate and clinical updates. At the end of October we announced that our partnership with Ono Pharmaceutical had ended following substantial non-dilutive financing that has fully fund
31-Oct-2024 6:00 AM CST - Business Wire Equillium Maintains Rights to Itolizumab Following Ono Partnership $EQ #GVHD--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that Ono Pharmaceutical Co., Ltd. (Ono) has made the strategic business decision to allow its option to acquire Equilliums rights to itolizumab to expire. The decision was not related to data from any clinical program and there have been no obse
